How to Sell an ABA Therapy Business or Autism Services Company in 2026: 6-13x EBITDA by Scale

If you plan to sell your autism services company or ABA therapy business in 2026, the price clears 6x EBITDA at the small end and into the low teens for scaled, well-run multi-site platforms with $1M-$5M+ EBITDA. The biggest value drivers are scale (a multi-site operation with a real management layer is worth far more per dollar than a single-clinic practice), payer mix and billing quality, BCBA and RBT recruitment and retention (clinician supply is the binding constraint), and management infrastructure that runs without the founding clinician. Active buyers include PE-backed autism/ABA platforms, larger ABA companies acquiring for geography, health systems, and payers building care delivery.

ABA therapy has been one of the most actively consolidated corners of healthcare, autism diagnoses keep rising, most states mandate commercial coverage, Medicaid funds a large share of services, and private equity has built platform after platform. Transaction volume has stayed high, with new PE platforms forming and existing platforms doing steady tuck-ins. But the difference between what a single clinic fetches and what a scaled, well-managed multi-site ABA platform fetches is enormous. This guide covers the multiples, the payer-mix and BCBA-retention math, the PE-backed buyers, what kills deals in diligence, and the process.

We are CT Acquisitions, an M&A advisory firm working both sides of the table with buyers in our network actively acquiring ABA therapy and autism services businesses (several with mandates specifically for autism, ABA, and IDD services). No fee to you on buy-side introductions; sell-side mandates are paid on success at closing. See also our guides on selling a behavioral health practice, selling a home health agency, and healthcare business valuation.

What ABA therapy business buyers actually pay for in 2026

Single-clinic or small ABA practice

Typical multiples: 4x to 6x SDE/EBITDA. One location, a small BCBA/RBT team, revenue tied to the founding clinician’s caseload and the local payer relationships. Buyer pool: larger regional ABA companies doing tuck-ins, individual BCBA-owner buyers, smaller platforms. Multiples reach the upper end when there is a stable clinician team beyond the owner, clean billing, a workable payer mix, and a smooth transition.

Multi-site ABA business with a management layer

Typical multiples: 6x to 9x EBITDA in the $1M-$5M EBITDA range. Several clinics, a roster of BCBAs and RBTs, intake/authorization/billing infrastructure, and a payer mix that holds up. PE-backed ABA platforms, larger ABA companies, and occasionally health systems compete here. Multiples reach the upper end when EBITDA is $3M+, the payer mix is balanced, clinician turnover is low with an active recruiting pipeline, documentation and authorization practices are clean, and the management team stays.

Scaled ABA platform

Typical multiples: low double digits, up to the low teens on EBITDA. Multi-state operations ($5M+ EBITDA), de novo-clinic-capable, with strong payer relationships, a deep clinical and operations bench, and demonstrated organic growth, command the top of the range, driven by payer and health-system demand for capacity and the scarcity of well-run scaled ABA assets.

The payer-mix and BCBA-retention math

The pattern is the same as broader behavioral health: ABA value is about whether the business is a scalable, well-run, payer-diversified, compliant care delivery organization with a clinician-recruiting engine, or a single-clinic clinician-dependent book. Move toward the former and the multiple moves with you.

The PE-backed platforms buying ABA therapy businesses in 2026

2026 buyer map: if you own an ABA therapy business and want the full sponsor-by-sponsor cap-table of the 15 active US PE platforms acquiring center-based, in-home, and school-based ABA practices in 2024-2026, with multiples by sub-segment and state-Medicaid rate impact on valuation, see the 2026 ABA Therapy PE Roll-Up Tracker. Every sponsor attribution corrected against primary CMS, BACB, and SEC sources.

• PE-backed autism / ABA platforms, private equity has built numerous ABA platforms over the past several years and continues to form new ones; transaction volume has stayed high, with platforms doing steady tuck-in acquisitions of multi-site and single-clinic businesses and acquiring larger groups as new platforms.
• Larger ABA companies, acquiring for geographic expansion, clinic density, and clinician capacity.
• Health systems and pediatric-services platforms, adding autism/ABA capability to a broader pediatric or behavioral health offering.
• Payers and managed care organizations, building or buying ABA delivery to manage access and cost for their members.
• Regional groups and individual BCBA-owner buyers, for smaller practices.

Note: several buyers in CT’s network have explicit mandates for autism, ABA, and intellectual and developmental disability services (some specifically non-physician-led healthcare services), this is a vertical where we have active demand.

Sell my autism services company: who buys, and the ABA acquisitions map

If you want to sell your autism services company, the strongest buyers today are the PE-backed ABA and autism platforms rolling up single-clinic and multi-site providers into regional groups. Your outcome depends on which platform is buying, your payer mix, and your BCBA retention, not on a headline multiple alone.

The autism services acquisition market is a roll-up. As covered in the platforms section above, a set of active PE-backed ABA platforms is consolidating the space, buying single-clinic practices and multi-site groups to build regional density. When owners search “sell my autism services company,” they are really asking which of these buyers fits their model, because a scaled acquirer with an in-market presence will pay differently than a first-time entrant looking for a foothold.

Which autism and ABA companies get acquired is driven by scale and clinical quality. Larger, multi-site businesses with recurring authorizations and stable BCBA retention command materially higher valuations than single-location practices, and the same buyers that pass on a solo clinic will compete hard for a platform with clean payer contracts. The 2026 ABA Therapy PE Roll-Up Tracker referenced above maps the active US platforms sponsor by sponsor, so you can see which acquirer is expanding in your region before your first conversation.

The practical move is to identify the two or three platforms already buying in your geography, then run a competitive process rather than accepting the first inbound offer. That is how a seller converts a roll-up market into real tension. To go deeper on positioning an autism or ABA practice for these buyers, see our sell your business resources.

The named ABA platforms and recent autism services deals

When you sell an autism services company, the buyer is usually one of a short list of PE-backed platforms, each built by acquiring independent clinics. A Brown University study published in JAMA Pediatrics on January 7, 2026 counted 574 PE-owned autism therapy centers across 42 states, assembled through 142 transactions. These are the platforms most often on the other side of the table:

Deal flow has not slowed. Mertz Taggart counted 30 autism and I/DD transactions in 2024, and the Braff Group reported 14 deals in the first quarter of 2025 alone. Sponsor ownership changes over time, so confirm the current owner of any platform before a first call. Our 2026 ABA therapy PE roll-up tracker keeps the full sponsor list with primary sources.

What this means for a seller. A single clinic rarely gets the attention of the largest platforms. A multi-site group with clean authorizations and stable BCBAs often draws several of them, plus a regional buyer looking for a foothold. The platform that already operates in your state values your payer contracts and staff differently from one entering the market, so map who is active near you before you take an inbound offer.

How to prepare an ABA therapy business for sale

• Clean up billing, authorization, and documentation. Reduce denials and AR aging, make sure treatment plans, authorizations, and session notes are defensible, fix credentialing gaps. ABA is audit-prone, this is the biggest diligence area, fix it before you list.
• Reduce founder-clinician dependency. Build clinical leadership below the owner (clinical director, regional BCBAs), transition oversight, and put operations leadership in place.
• Document and balance the payer mix. Show the commercial/Medicaid breakdown, contracts, and rates by payer; diversify away from over-reliance on a single payer.
• Build a BCBA/RBT recruiting pipeline and reduce turnover, document your hiring funnel, ramp time, retention, and clinician productivity. This is a major value lever.
• Show your waitlist / unmet demand by market, it’s the buyer’s organic growth case.
• Tighten operations metrics, billable hours per clinician, authorization-to-service conversion, no-show/cancellation rates, intake-to-treatment timelines.
• Clean financials, accrual accounting, normalized owner comp, documented add-backs, 2-3 year review, and clear unit economics by clinic.

What kills ABA therapy business deals in diligence

• Billing, authorization, and documentation problems, denials, aged AR, weak treatment-plan or session-note documentation, audit exposure
• Credentialing gaps that block expansion or create revenue risk
• Founder-clinician dependency, the clinical oversight and payer relationships run through one person
• BCBA/RBT turnover or a thin clinician bench with no recruiting pipeline
• Payer concentration or over-reliance on a single Medicaid plan or commercial payer
• Low billable utilization or unclear clinic-level unit economics
• Compliance flags, billing-for-services-not-rendered exposure, supervision-ratio issues
• Sloppy financials that don’t normalize owner comp or show clinic-level economics

The process: first conversation to close

Off-market to a PE-backed ABA platform, larger ABA company, health system, or payer: roughly 90-180 days, days 1-14 conversation/valuation/fit, days 14-30 buyer introductions, days 30-60 LOI, days 60-150 diligence (financials, billing/authorization/documentation review, payer-contract and credentialing analysis, clinician roster and retention, compliance, corporate structure) and definitive agreement, days 120-180 close and transition. Traditional broker listings take 9-18 months. See our broker alternative guide.

Related: selling a behavioral health practice, selling an ABA therapy business, selling a home health agency, healthcare business valuation, CPA business valuation, how to value a small business, private equity value creation, the business broker alternative.

The five pillars of how CT Acquisitions works

About the Author

Christoph Totter is the founder of CT Acquisitions, an M&A advisory firm working both sides of the table, headquartered in Sheridan, Wyoming. We work directly with 500+ buyers, search funders, family offices, lower middle-market PE, and strategic consolidators, including direct mandates with the largest consolidators that other intermediaries cannot access. No fee to you on buy-side introductions; sell-side mandates are paid on success at closing. Connect on LinkedIn · Get in touch

Frequently asked questions

Who buys autism services and ABA therapy companies?

The most active buyers are PE-backed ABA and autism platforms consolidating the market, alongside strategic regional groups adding clinical capacity. Single-clinic practices tend to attract first-time platform entrants, while multi-site groups with strong payer contracts draw competing bids from scaled acquirers.

How much is my ABA therapy business worth?

Single-clinic or small ABA practices typically sell for 4x to 6x SDE/EBITDA, because revenue is clinician-dependent. Multi-site ABA businesses with a management layer (roughly $1M-$5M EBITDA) sell for 6x to 9x EBITDA. Scaled ABA platforms (multi-state, $5M+ EBITDA, de novo-capable) reach the low double digits, up to the low teens on EBITDA. The biggest multiple drivers are scale, payer mix and billing/authorization/documentation quality, BCBA and RBT recruitment and retention, and a management infrastructure independent of the founding clinician. Use our free valuation tool for a sector-adjusted estimate.

What makes an ABA therapy business more valuable?

Scale (more clinics, more clinicians beyond the owner, more EBITDA, valued at a higher multiple per dollar); a balanced commercial + Medicaid payer mix with clean billing, low denials, and defensible authorization and documentation practices; strong payer contracts and credentialing across locations; a BCBA/RBT recruiting engine and low turnover (clinician supply is the binding constraint); healthy billable utilization; a management infrastructure (intake, authorization, scheduling, billing, credentialing) that runs without the founder; a visible waitlist of unmet demand; and clean accrual financials with normalized owner comp and clinic-level unit economics. The billing/documentation cleanup and reducing founder dependency are the biggest levers.

Who is buying ABA therapy businesses in 2026?

PE-backed autism/ABA platforms (private equity has built numerous ABA platforms and continues forming new ones; transaction volume has stayed high with steady tuck-in activity); larger ABA companies expanding geography and clinic density; health systems and pediatric-services platforms adding autism/ABA capability; payers and managed care organizations building or buying ABA delivery; and regional groups and individual BCBA-owner buyers for smaller practices. CT also has buyers in its network with explicit mandates for autism, ABA, and intellectual and developmental disability services.

Why is ABA M&A so active?

Autism diagnoses keep rising, most states mandate commercial coverage of ABA, Medicaid funds a large share of services, and demand for ABA vastly exceeds the supply of BCBAs and RBTs. That structural demand, plus payer and health-system pressure to expand access, plus private equity’s appetite for fragmented healthcare-services rollups, has kept ABA transaction volume high for years, with new platforms forming and existing platforms doing steady tuck-ins. Multiples for scaled, well-run platforms reach the low teens; smaller clinician-dependent practices get less, but the sector overall trades well above generic small-business multiples.

How does my payer mix and billing affect what my ABA business is worth?

A lot. Buyers want collectible, durable revenue. A balanced commercial-plus-Medicaid mix, with clean claims, low denial rates, and defensible authorization and documentation practices, is far more valuable than a business with billing problems or heavy reliance on a single payer. ABA billing is authorization-driven and audit-prone, so documentation quality (treatment plans, authorizations, session notes, supervision ratios) is the single biggest diligence factor; weak documentation gets deals repriced or killed. Clean it up before you go to market and present clear payer-mix, denial, and AR-aging metrics.

How do I increase the value of my ABA therapy business?

Clean up billing, authorization, and documentation (the biggest diligence area, reduce denials and AR aging, make treatment plans/authorizations/session notes defensible, fix credentialing); reduce founder-clinician dependency (build clinical leadership below the owner, install operations leadership); document and balance the payer mix; build a BCBA/RBT recruiting pipeline and lower turnover; surface your waitlist of unmet demand; tighten operational metrics (billable utilization, intake-to-treatment timelines); and get clean accrual financials with normalized owner comp and clinic-level unit economics. The billing cleanup and founder-dependency reduction can be materially improved in 12-24 months.

How long does it take to sell an ABA therapy business?

Traditional broker-listed ABA businesses typically take 9-18 months. Off-market sales to PE-backed ABA platforms, larger ABA companies, health systems, or payers typically take 90-180 days, because the buyer is pre-qualified and actively looking to acquire in your geography, size range, and payer footprint, and ABA diligence (financials, billing/authorization/documentation, payer contracts and credentialing, clinician roster, compliance, corporate structure) is well-trodden ground for these buyers.

Do I need a broker to sell my ABA therapy business?

For a single clinic, a healthcare-focused business broker can work but charges 8-15% commissions. No fee to you on buy-side introductions; sell-side mandates are paid on success at closing. Some sellers sell directly to a known platform with just healthcare transactional counsel, but a competitive process almost always lifts the price, especially given how many active ABA acquirers there are.

Which autism services companies have been acquired recently?

Recent deals include Tenex Capital Management buying Behavioral Innovations from Shore Capital Partners in June 2024, GTCR closing its purchase of Caravel Autism Health in July 2024, and Nautic Partners buying Proud Moments ABA from Audax in February 2025. KKR-backed BlueSprig added Trumpet Behavioral Health in October 2023. Each platform keeps buying independent clinics.

How many autism therapy centers are owned by private equity?

A Brown University study published in JAMA Pediatrics on January 7, 2026 identified 574 PE-owned autism therapy centers across 42 states, built through 142 transactions. That concentration is why most sellers of multi-site ABA businesses end up talking to the same group of platform buyers.

Do Medicaid rate cuts lower what my ABA business sells for?

They can. Buyers model revenue on current state rates, so a cut in your largest state shows up in price or deal structure. New York Medicaid lowered its rate for CPT 97153 from $16.85 to $14.45 per unit on April 1, 2026, per NY Medicaid Update. Sellers with a balanced commercial mix feel these cuts less.

Related research

• Free Business Valuation Tool, your business is worth in 90 seconds
• The Business Broker Alternative Guide (national pillar)
• Business Brokers by State, with a free alternative
• The Complete Guide to Selling Your Business in 2026
• What’s My Business Worth? Founder’s Valuation Guide
• Who Buys These Companies? Buyer Types Explained
• How to Sell to Private Equity, A Founder’s Walkthrough
• Owner’s Pre-Exit Checklist, 90 Days Before You List
• CT Commentary, Founder & M&A Insights